These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 38341667)

  • 1. Activating CD8
    Wang B; Zhou J; Li R; Tang D; Cao Z; Xu C; Xiao H
    Adv Mater; 2024 May; 36(21):e2311640. PubMed ID: 38341667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tackling Esophageal Squamous Cell Carcinoma with ITFn-Pt(IV): A Novel Fusion of PD-L1 Blockade, Chemotherapy, and T-cell Activation.
    Xin Q; Wang D; Wang S; Zhang L; Liang Q; Yan X; Fan K; Jiang B
    Adv Healthc Mater; 2024 Apr; 13(11):e2303623. PubMed ID: 38142309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
    Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J
    Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blocking of the PD-1/PD-L1 interaction by a novel cyclic peptide inhibitor for cancer immunotherapy.
    Zhai W; Zhou X; Zhai M; Li W; Ran Y; Sun Y; Du J; Zhao W; Xing L; Qi Y; Gao Y
    Sci China Life Sci; 2021 Apr; 64(4):548-562. PubMed ID: 32737851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanodrug modified with engineered cell membrane targets CDKs to activate aPD-L1 immunotherapy against liver metastasis of immune-desert colon cancer.
    Ding D; Liang R; Li T; Lan T; Li Y; Huang S; He G; Ren J; Li W; Zheng Z; Chen T; Fang J; Huang L; Shuai X; Wei B
    J Control Release; 2024 May; 369():309-324. PubMed ID: 38554771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
    Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
    Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DTX@VTX NPs synergy PD-L1 immune checkpoint nanoinhibitor to reshape immunosuppressive tumor microenvironment for enhancing chemo-immunotherapy.
    Zhang R; Wan Y; Lv H; Li F; Lee CS
    J Mater Chem B; 2021 Sep; 9(36):7544-7556. PubMed ID: 34551052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade.
    Qin Y; Vasilatos SN; Chen L; Wu H; Cao Z; Fu Y; Huang M; Vlad AM; Lu B; Oesterreich S; Davidson NE; Huang Y
    Oncogene; 2019 Jan; 38(3):390-405. PubMed ID: 30111819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple-Combination Immunogenic Nanovesicles Reshape the Tumor Microenvironment to Potentiate Chemo-Immunotherapy in Preclinical Cancer Models.
    Shi X; Shu L; Wang M; Yao J; Yao Q; Bian S; Chen X; Wan J; Zhang F; Zheng S; Wang H
    Adv Sci (Weinh); 2023 May; 10(15):e2204890. PubMed ID: 37017572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Synergistic Chemoimmunotherapy System Leveraging PD-L1 Blocking and Bioorthogonal Prodrug Activation.
    Wang K; Jiang M; Li T; Liu Y; Zong Q; Xu Q; Ullah I; Chen Y; Xue W; Yuan Y
    Adv Mater; 2024 Jul; 36(30):e2402322. PubMed ID: 38718226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Precision USPIO-PEG-SLe
    Li T; Guo L; Li J; Mu X; Liu L; Song S; Luo N; Zhang Q; Zheng B; Jin G
    Int J Nanomedicine; 2024; 19():1249-1272. PubMed ID: 38348177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.
    Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X
    Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist.
    Knudson KM; Hicks KC; Ozawa Y; Schlom J; Gameiro SR
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spatiotemporal-Controlled NIR-II Immune Agonist Sensitizes Cancer Immunotherapy.
    Guo S; Tang D; Zhang M; Yang H; Zhang T; Hu B; Xu C; Weng Y; Shang K; Huang Y
    Adv Mater; 2024 Jun; 36(25):e2400228. PubMed ID: 38477852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Laser/GSH-Activatable Oxaliplatin/Phthalocyanine-Based Coordination Polymer Nanoparticles Combining Chemophotodynamic Therapy to Improve Cancer Immunotherapy.
    Huang Z; Chen Y; Zhang J; Li W; Shi M; Qiao M; Zhao X; Hu H; Chen D
    ACS Appl Mater Interfaces; 2021 Aug; 13(33):39934-39948. PubMed ID: 34396771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death.
    Moon Y; Shim MK; Choi J; Yang S; Kim J; Yun WS; Cho H; Park JY; Kim Y; Seong JK; Kim K
    Theranostics; 2022; 12(5):1999-2014. PubMed ID: 35265195
    [No Abstract]   [Full Text] [Related]  

  • 17. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
    Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining Nanomedicine and Immunotherapy.
    Shi Y; Lammers T
    Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phenolic based tumor-permeated nano-framework for immunogenic cell death induction combined with PD-L1 immune checkpoint blockade.
    Sun X; Zhang J; Xiu J; Zhao X; Yang C; Li D; Li K; Hu H; Qiao M; Chen D; Zhao X
    Biomater Sci; 2022 Jul; 10(14):3808-3822. PubMed ID: 35670432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using pH-responsive hybrid membrane-coated nanoparticles.
    Gong C; Yu X; Zhang W; Han L; Wang R; Wang Y; Gao S; Yuan Y
    J Nanobiotechnology; 2021 Feb; 19(1):58. PubMed ID: 33632231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.